Form 4: Tandem Diabetes Care Director Christopher Twomey Reports Stock Transactions
SEC Form 4
Director Christopher Twomey reports acquisition and disposal of Tandem Diabetes Care stock and restricted stock units.
Summary
- On May 24, 2024, Christopher Twomey, a director of Tandem Diabetes Care Inc., reported transactions involving the company's stock.
- Twomey acquired 4,434 shares of common stock through the exercise of restricted stock units at a price of $51.73 per share.
- He also reported the acquisition of 4,387 restricted stock units on May 22, 2024, which will vest on the one-year anniversary of the grant date.
- Following these transactions, Twomey directly owns 11,288 shares and indirectly owns 5,112 shares through a family trust and 7,568 shares through Twomey Family Investments, LLC.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of stock transactions by a company director.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, which is common in the healthcare and medical device industry.
Key Dates
| Date | Description |
|---|---|
| 09/20/2002 | Date of Chris J. Twomey and Rebecca J. Twomey Family Trust UTD |
| 05/24/2023 | Restricted Stock Unit awarded pursuant to the 2023 Plan |
| 05/22/2024 | Restricted Stock Unit awarded pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan |
| 05/24/2024 | Date of stock transaction and filing of Form 4 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.